Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
about
Recycling side-effects into clinical markers for drug repositioningMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsRapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinibMolecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.Guide to interpreting disease responses in chronic myeloid leukemia.Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinLung cancer: Biology and treatment options.Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinaseCardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged SwordOutcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.Emerging therapeutic targets in breast cancer bone metastasis.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Treatment of chronic myeloid leukemia when imatinib fails.Chronic myelogenous leukemia: monitoring response to therapy.Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Chronic myeloid leukemia: overview of new agents and comparative analysis.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.Different role of cAMP pathway on the human mast cells HMC-1(560) and HMC-1(560,816) activation.Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.Disseminated intravascular coagulation following administration of sunitinib.Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.Antibody-drug conjugates for non-oncological indications.Dasatinib-induced nephrotic syndrome.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
P2860
Q28482438-F1ACC324-6651-4C0D-AA47-ABB45B58B812Q28551045-5CCDB07C-CFD0-4FF8-AEC3-94E7DC3E9C09Q33404602-888E693F-DAEB-480C-9A13-996A334CC70FQ33434675-33A8AF80-7B37-4875-9940-0B5A1217E1C1Q33655352-F938B559-ABBF-4742-B457-89E1687CE14DQ33770326-889DB125-52F9-4DD7-9C78-73846E98F0A5Q33885637-DE3EBFD6-CEE1-4254-BCAD-71C1DED8E0E5Q34808070-C4F16D4B-1C97-4046-8A0F-8270BB21923EQ35717808-0A57FF26-AB90-41A7-B53B-42E5464E65E7Q36328370-9E96585B-AB70-4DF4-953A-E97BDBA10BC3Q36694985-14B92133-5A6C-4C92-8D6F-5EEE02348B03Q36721511-E05ABBDD-2888-4B2D-9A4D-884D85022D11Q36862301-C990208C-DD47-41B7-BDC5-20B7E62EA92FQ37369583-3638E62F-019E-4263-86DF-1CF331B2E9E0Q37658767-2FBEB600-A03C-4339-86E0-DA0134876C66Q37781050-D58417B2-6977-44CF-A18C-5A84623B9FA7Q37827875-B52E1A6A-3FAB-44F9-A404-19B2B7B631BCQ37848207-848A0EFD-B687-46E1-AA9F-03A85355AC65Q37999108-F6DD6ECD-5B6A-40DB-B267-5F596281C01CQ38095848-5AB1B7E8-7212-44A1-A317-69537260AEBEQ38097728-1EBABF3B-EB18-4571-8F8B-DB395107C977Q38457554-61908709-A4F4-43B3-833C-DB2E7918D7D9Q38707841-39A85050-46B0-44DA-9C2F-CD6DCA6771A4Q38829019-F058EB2F-254B-4FAC-A4D2-D8FD0E8E35D9Q38845834-BB60BA28-3D78-41B6-AF6B-BF63A0A97D6BQ39035187-AEB25BFB-CB12-4EFD-AFB6-D9CA99048507Q39048486-267DDB70-2C4B-43A9-8A1F-F52300E6AE96Q39459161-987CC8E1-3E48-41B5-9FAD-3EFE192244A8Q40188101-CFE0BCC5-FECB-4E3A-B142-CDAA0D79B936Q40688319-4B4E70B3-A6CF-42E3-8F2F-ACCAEE82E49AQ42036021-8A435CAB-4CC0-4773-87A5-496C39297836Q42283940-0039C9D3-3F3F-44A6-8E3C-885783A25EDFQ42796997-A4362E62-380A-4C91-B1D2-E58EF2CA5FDCQ43059186-FD88445F-3C4C-4C71-8048-C60591C127D4Q46036446-84021677-AC4C-4E45-B0A2-345F6B8974E6Q54242433-9D659DF0-8745-43F8-89B6-47F064E6209FQ54546815-281784EC-4756-4F3C-BEB6-479DA4E7BE96
P2860
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@en
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@nl
type
label
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@en
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@nl
prefLabel
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@en
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2009.111
P577
2009-05-28T00:00:00Z